( that these MDIs arefunctional in vitr...)Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice,Health

that these MDIs are functional in vitro and when transplanted into stz-induced NOD/SCID mice is a breakthrough for our adult stem cell program. The differentiation of MDIs derived from MDSCs produced from type 1 and type 2 diabetics is a major advance in the development of a cell replacement therapy for the treatment of diabetes."

"These presentations by Dr. Winnier demonstrate significant advancement of our stem cell development program and serve as proof-of-principle for our adult diabetes mellitus beta-cell replacement therapy development", said David McWilliams, chief executive officer. "The potential use of adult MDSCs for the development of functional MDIs maybe a viable alternative to the development of islet cells derived from embryonic stem cells."

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forwa
'"/>

Page: 1 2 3
Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Monitoring Patient Glucose Levels: New Advances in software make it easier
5. New Advances in Gastric Diagnostics: Smaller is Better
6. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
7. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
8. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak